

PI Major Mutations:	None
PI Accessory Mutations:	None
PR Other Mutations:	I13V 10% <small>seen=1,435</small> • G16E 100% <small>seen=1,438</small>
Protease Inhibitors	
atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
fosamprenavir/r (FPV/r)	Susceptible
indinavir/r (IDV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible
nelfinavir (NFV)	Susceptible
saquinavir/r (SQV/r)	Susceptible
tipranavir/r (TPV/r)	Susceptible

No drug resistance mutations were found for PI.

NRTI Mutations:	None
NNRTI Mutations:	None
RT Other Mutations:	E514D 100% <small>seen=1,300</small> • E516HQ 10% <small>seen=1,542</small> • Q524K 10% <small>seen=2,082</small> • K527KE 1% <small>seen=12,686</small> • E529D 10% <small>seen=2,082</small> • K530QR 1% <small>seen=12,686</small> • A534S 100% <small>seen=6,178</small> • A554S 100% <small>seen=6,362</small> • K558R 100% <small>seen=1,754</small>
Nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible
zidovudine (AZT)	Susceptible
stavudine (D4T)	Susceptible
didanosine (DDI)	Susceptible
emtricitabine (FTC)	Susceptible
lamivudine (3TC)	Susceptible
tenofovir (TDF)	Susceptible
Non-nucleoside Reverse Transcriptase Inhibitors	
doravirine (DOR)	Susceptible
efavirenz (EFV)	Susceptible
etravirine (ETR)	Susceptible
nevirapine (NVP)	Susceptible
rilpivirine (RPV)	Susceptible

No drug resistance mutations were found for NRTI.

No drug resistance mutations were found for NNRTI.

INSTI Major Mutations:	None
INSTI Accessory Mutations:	None
IN Other Mutations:	R20RK 1% <small>seen=2,302</small> • I72V 100% <small>seen=1,438</small> • L74I 100% <small>seen=1,438</small> • E96D 100% <small>seen=1,319</small> • T112I 100% <small>seen=1,082</small> • I113V 100% <small>seen=1,082</small> • T124N 100% <small>seen=1,036</small> • T125A 100% <small>seen=1,036</small> • V126M 100% <small>seen=1,036</small> • K136Q 100% <small>seen=1,382</small> • D167E 100% <small>seen=1,320</small> • K173R 100% <small>seen=1,634</small> • V201I 100% <small>seen=1,214</small> • I203IM 1% <small>seen=15,796</small> • I208L 100% <small>seen=1,200</small> • L234I 100% <small>seen=1,312</small> • S283G 10% <small>seen=1,130</small> • D288N 100% <small>seen=1,942</small>
Integrase Strand Transfer Inhibitors	
bictegravir (BIC)	Susceptible
cabotegravir (CAB)	Susceptible
dolutegravir (DTG)	Susceptible
elvitegravir (EVG)	Susceptible
raltegravir (RAL)	Susceptible

IN comments

Other

- L74I is a highly polymorphic mutation with a prevalence of 3% to 30% depending on subtype. It is the consensus amino acid in subtype A viruses belonging to the A6 clade. It does not appear to be selected by any of the INSTIs or to reduce their susceptibility.

No drug resistance mutations were found for INSTI.